Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501).
Watanabe S, Sakai K, Matsumoto N, Koshio J, Ishida A, Abe T, Ishikawa D, Tanaka T, Aoki A, Kajiwara T, Koyama K, Miura S, Goto Y, Sekiya T, Suzuki R, Kushiro K, Fujisaki T, Yanagimura N, Ohtsubo A, Shoji S, Nozaki K, Saida Y, Yoshizawa H, Nishio K, Kikuchi T.
Watanabe S, et al. Among authors: abe t.
Cancers (Basel). 2022 Dec 29;15(1):204. doi: 10.3390/cancers15010204.
Cancers (Basel). 2022.
PMID: 36612200
Free PMC article.